

Declaration of Interests Register

TA Committee D

Publication Date: 01/05/2019

Topic: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr. Fiona McDonald	Clinical Expert	Direct - financial	Received a consultancy fee from the company for attending an advisory board	N/A	N/A	N/A	No dates were provided
Prof. Matthew Hatton	Clinical Expert	Direct - financial	Received a fee to attend an AstraZeneca advisory board	2017	2019	2017	N/A
Peter Hall	Committee D Member	Indirect - financial	Institutional research funding from AstraZeneca	N/A	N/A	N/A	No dates were provided

Link to Committee D interests register : <https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/TAC-D-interests-register.pdf>